Background: Chronic kidney disease (CKD) is becoming a serious health problem; the number of people with impaired renal function is rapidly rising. Progression of CKD is associated with having a number of complications, including thyroid dysfunction, dyslipidemia, and cardiovascular diseases.
Introduction
Chronic kidney disease (CKD) is becoming a serious health problem; the number of people with impaired renal function is rapidly rising, especially in industrialized countries.
[1] Recent time reports, however, suggest an abrupt rise importantindependent predictors of cardiovascular morbidity and mortality. [7] Several factors contribute to the development of dyslipidemia associated with chronic renal impairment. Patients with CKD have a reduction in the activity of lipoprotein lipase and hepatic triglyceride lipase. This interferes with uptake of triglyceride rich, apolipoprotein B containing lipoproteins by the liver and in peripheral tissue, yielding increased circulation of these atherogenic lipoproteins. [4] Progression of CKD is accompanied by the development of specific alterations of the lipoprotein metabolism. [8] Reports show that mortality due to CVD was 10-30 times higher in dialysis patients than in the general population. [9] There is growing evidence that abnormalities in lipid metabolism may contribute to renal disease progression. [10] Thyroid dysfunction and dyslipidemia in CKD may further increase CVD risk leading to increased morbidity and mortality. Hence, early diagnosis of thyroid and lipid disorders by regular screening, and treatment of such disorders in patients with CKD may be highly beneficial to slow the progression of CKD, in addition to the prevention of CVD risk. [4, 6] A study in Hapur (U.P.), reported CKD in 10.6% of general community with age and diabetes mellitus being the significant predictors for CKD. [11] Another small study reported dyslipidemia to be very common in Indianpatients with CKD. [12] In view of the decreased thyroid function and dyslipidemia in patients with CKD, and the lack of data for thyroid function and dyslipidemia in Indian population with CKD, the present study was undertaken in the population with CKD.
Material and Methods
A cross-sectional study was conducted among patients with CKD attending biochemistry laboratory of Saraswathi Institute of Medical Sciences, Hapur (U.P.) from February 2016 to July 2016 to investigate thyroid function and lipid profile in patients with CKD of stages 3-5. A total of 90 newly diagnosed and known CKD cases (stage 3-5) were included in the study. CKD was defined on the basis of National Kidney Foundation guidelines of having an estimated glomerular filtration rate (eGFR) <60 mL/min/1.732 m 2 for more than 3 months. The Modification of Diet in Renal Disease study (MDRD) equation was used to calculate eGFR. [13] Patients with known thyroid disorders, on medications affecting thyroid function and on lipid lowering agents were excluded from the study. The study protocol was approved by the SaraswathiInstitute of Medical Sciences, Hapur and consents were obtained from each patient.
Demographic features (age and sex) and medical history of diabetes mellitus, hypertension, and CVD of each patient were noted, and blood samples (5 mL) were collected. CVD was defined as a history of coronary heart disease, congestive heart failure, peripheral arterial disease, or stroke. Blood was analyzed for serum urea, creatinine, glucose, total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, triglyceride, triiodothyronine (T3), thyroxine (T4), and thyroid stimulating hormone (TSH). Serum urea level and blood glucose were estimated using enzymatic methods and creatinine by the Jaffe method.
Serum free T3, free T4, and TSH were measured by using fluorescent immunoassay (VIDAS, biomeriux SA, France). Similarly, total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides were measured using kits from AGAPPE diagnostics by Biolyzer 100. Thyroid dysfunction was considered if patients thyroid hormones fall outside the reference range; free T3 (4.0-8.3 pmol/L), free T4 (9.0-20.0 pmol/L), and TSH (0.25-5 mIU/L). Euthyroid was considered if thyroid hormone levels fall within reference range. Overt hypothyroidism was defined as TSH > 5mIU/L and free T3 < 4.0 pmol/L and free T4 < 9.0 pmol/L. Subclinical hypothyroidism was considered if TSH > 5 mIU/L and free T3 and free T4 within reference range. Subclinical hyperthyroidism was defined as TSH < 0.25 mIU/L and free T3 and free T4 within reference range. The data generated from study was entered into MS excel and analyzed using SPSS version 11.0. The data were expressed as mean ± SD(for normal distribution) and median (for non-normal distribution) for continuous variables and as percentage (number) for categorical variables. Oneway ANOVA and Kruskal-Wallis test were applied for continuous variables and Chi-square test for categorical variables at 95%confidence interval.
Results
The present study population comprised of 90 patients with CKD with 53.8%males and 46.1% females. The mean age of study population was 44. The odds ratio of having thyroid dysfunction and CVD in patients with CKD due to various risk factors is shown in Table 3 . There were significant odds of having thyroid dysfunction in stages 4 and 5 as compared to stage 3 CKD. The data is presented as mean ± SD (except for TSH level which showed non-normal distribution and is expressed as median) for continuous variables and as percentage (number) for categorical variables. P value was calculated at 95 % confidence interval among CKD stages 3-5 for different variables using one way ANOVA and Kruskal Wallis test for continuous variables, and chi square test for categorical variables [19] In the present study, it was found that stages 4 and 5 patients had significantly high risk for thyroid dysfunction as compared to stage 3 patients, which is consistent with the findings of Lo et al, who observed increased risk for hypothyroidism with the decrease in GFR. [6] Song et al, also observed a positive relationship between eGFR and serum T3 and after adjusting for age and sex, compared with eGFR ≥ 60mL/min/1.73m 2 , eGFR < 60mL/ min/1.73m 2 was associated with an increased odds of low T3 (odds ratio 2.40). [19] In a study in Saudi Arabia, there was a significant decrease in the levels of serum total T3, total T4 and total protein and albumin levels in patients with CKD when compared with the controls. There was a significant increase in the level of TSH in the patients with CKD compared with the controls. [20] However, a study in undialyzed patients with CKD found that both T3 and T4 were significantly reduced whereas TSH remains to be unchanged in patient group compared to controls. [21] Subclinical hypothyroidism was found (27.2%) to be very common in patients with CKD. It has been estimated that the prevalence of subclinical hypothyroidism ranges between 4%
Discussion
The present study identifies thyroid dysfunction and dyslipidemia as a common disorder in Indianpatients with CKD. Thyroid dysfunction was found in 38.6% patients with CKD, the most common being subclinical hypothyroidism (27.2%), followed by overt hypothyroidism (8.1%) and subclinical hyperthyroidism (3.3%). Higher prevalence of thyroid dysfunction was observed in patients with CKD than shown by other studies. A small study in hemodialysis patients in western U.P.showed the combined prevalence of subclinical and clinical hypothyroidism in 26.6%patients. [14] Study by Lo et al found that the prevalence of hypothyroidism increased with lower levels of GFR (in units of mL/min/1.73m
2 ), occurring in 5.4%of subjects with GFR greater than or equal to 90, 10.9% with GFR 60-89, 20.4% with GFR 45-59, 23.0% with GFR 30-44, and 23.1%with GFR < 30 (p < 0.001 for trend). They reported that 56%of hypothyroidism cases were subclinical. [6] In a study in India among end stage renal failure (ESRD) patients, prevalence of subclinical hypothyroidism was 24.8%. [15] A study by Ng et al in peritoneal dialysis (PD) patients of Taiwan reported that, 98 (80.3%) were having euthyroidism; 19 (15.6%) subclinical hypothyroidism and 5 (4.1%), subclinical hyperthyroidism. [16] High rate of thyroid dysfunction in patients with CKD as observed in our study may also be due to high prevalence of thyroid autoimmunity in study population, excess iodine nutrition or iodine deficiency, and the inclusion of subjects with non-thyroidal illness. [17, 18] Decreasing trend for free T3 and free T4 levels was observed (though the decrease were not significant), and increasing trend for TSH level (significant rise) across CKD and 10%in the general population and it has been well observed that hypothyroidism (overt or clinical) increases the risk for CVD. Subclinical hypothyroidism has been identified as a strong predictor of all-cause mortality in chronic dialysis patients and as a risk factor for nephropathy and cardiovascular events in type 2 diabetic patients. [22] In the present study, however, significant risk of having CVD was not observed in patients with CKD with thyroid dysfunction especially subclinical. [23, 24] hypothyroidism as compared to those with normal thyroid function. A number of studies have reported that subclinical hypothyroidism is associated with an increased risk of coronary heart disease and there appears to be a significant increase in a cluster of metabolic CVD risk factors among people with subclinical hypothyroidism. The reduced T3 level, the reduced free T4 levels along with an elevated TSH raises the possibility of benefit from thyroid supplementation in CKD. However, it is still debatable about the importance and necessity of thyroid hormone supplementation in patients with CKD and concrete evidence is not available for recommending supplementation of thyroid hormones in patients with CKD. [25] In general, the prevalence of hyperlipidemia increases as renal function declines, with the degree of hypertriglyceridemia and elevation of LDL cholesterol being proportional to the severity of renal impairment. [4] CKD affects lipoprotein metabolism, leading to hypercholesterolemia, hypertriglyceridemia and excess LDL cholesterol. [26] In the present study, dyslipidemia was reported in significant number of patients with CKD. Hypercholesterolemia, low HDL, undesirable LDL and hypertriglyceridemia was observed in 34.4%, 34.1%, 35%, and 36.6%patients, respectively. Our finding are similar to the results of a study in Gajiabad, U.P., where hypercholesterolemia, low HDL cholesterol, high LDL cholesterol and hypertriglyceridemia was present in 33.75%, 32.5%, 38.03%, and 35.58%patients with CKD, respectively, and patients with CKD had higher odds of developing dyslipidemia as compared to non-CKD controls. [12] However, no significant odds of developing dyslipidemia were observed in stages 4 and 5 patientsas compared to stage 3 patients. Many studies have reported rise in level of lipid parameters and dyslipidemia prevalence in patients with CKD, which may further assist in renal disease progression. [10] Study by Raju et al found that there was a significant increase of serum triglycerides and very low-density lipoprotein (VLDL) with a decrease in serum HDL cholesterol in both non-dialysis and hemodialysis groups of patients with CKD when compared with control. But there was no alteration in serum total cholesterol and LDL cholesterol in both groups. [27] Dyslipidemia in CKD may have significant impact, especially for CVD risk. [7] Our finding suggest for the significant association between the presence of cardiovascular disease with hypercholesterolemia and high LDL cholesterol in patients with CKD. Our study reveals that CKD progression is strongly associated with CVD prevalence. Stage 4 and stage 5 patients had higher risk for having CVD as compared to stage 3 patients. The study however, did not find significant rise in dyslipidemia cases during CKD progression. A large number of epidemiologic studies have suggested the independent role of dyslipidemia on cardiovascular morbidity and mortality in the general population. [10] But, the role of dyslipidemia in the pathophysiology of atherosclerotic disease in patients with CKD remains controversial. Some studies have shown a positive association between cholesterol values and the risk for cardiovascular events in CKD individuals, whereas others failed to find any significant correlation. Although the precise causes of this significant deviation from what is observed in the general population have not been established, it has been proposed that the presence of phenomena such as inflammation or protein energy wasting (conditions very common in ESRD patients) may significantly confound the relationship between the traditional risk factors for CVD and mortality in CKD patient population. [26] Study by Chen et al demonstrated that certain levels of dyslipidemia were independently associated with renal replacement therapy and rapid renal progression in CKD stage 3-5. Thus, assessment of lipid profile in patients with CKD may help identify high risk groups with adverse renal outcomes. [10] Among, the various risk factors for CVD considered, only diabetes had significant association with CVD occurrence. Diabetic condition had also significant association with progression of CKD. Diabetes is said to be the leading cause of CKD in many populations and is associated with excessive cardiovascular morbidity and mortality. [28] Thyroid disorders and CKD are independently some of the most prominent medical conditions found in patients in many countries. Clinicians, including nephrologists, must consider the dangers of thyroid disease and its appropriate treatment in conjunction to treating CKD. Thyroid dysfunction causes significant changes in kidney function and kidney diseases can be associated with thyroid disorders. Thus, both CKD and thyroid dysfunction mutually influence each other. [29] Similarly, dyslipidemia is the leading risk factor for CVD in patients with CKD, and CVD remains the leading cause of death in patients with CKD. Kidney Disease Outcomes Quality Initiative (K/DOQI) working group has suggested that, all adults and adolescents with CKD should be evaluated for dyslipidemias because of high risk for CVD. [30] Our findings of present study have great clinical significance. It suggest for the importance of regular screening and treatment of thyroid dysfunction and dyslipidemia in patients with CKD, which may further help to prevent CVD risk. This would help in better clinical management of patients with CKD and thus better quality of life. So, regular checkup of thyroid function and lipid profile was recommended in patients with CKD. It should be however noted that, since the study was conducted in a region of poor socio-economic status where conditions (nutrition status, disease status, thyroid autoimmunity status, genetic components) of patients may be slightly different than other parts of world, the present findings may vary somewhat for other regions. The present study has some limitations which should be noted. First, patients with non-thyroidal illness (which is typically seen in some ill patients, including those with end-stage renal disease) were not identified, since thyroid testing was done only once. This may have resulted in higher rate of thyroid dysfunction in the present study due to inclusion of some patients with non-thyroidal illness. Second, the iodine status of the subjects was not studied, so excess iodine nutrition or iodine deficiency in these regions may contribute to thyroid disorders, mainly subclinical hypothyroidism. [18] Third, thyroid autoimmunity status was not assessed in the study population. High prevalence of thyroidal autoimmunity is related with increased thyroid dysfunction, so high rate of thyroid autoimmunity (if present) may have contributed for high thyroid dysfunction rate in the present study. [17] Further studies should explore potential causal mechanisms through which CKD may be associated with increased TSH and reduced thyroid function, including the possible roles of autoimmunity and iodine excess, and the mechanism of dyslipidemia in patients with CKD.
Conclusions
In summary, the present study finds thyroid dysfunction to be very common in patients with CKD and reveals the significant association between CKD progression and thyroid dysfunction. The study also finds dyslipidemia as a common disorder in CKD. The study reveals that patients with CKD with elevated lipid parameters have strong risk for developing CVD, so early treatment for lipid abnormalities in patients with CKD may lower the chance of developing CVD later.
